在非小细胞肺癌中,RASON促进KRASG12C驱动的瘤进展和免疫逃避
Jianzhuang Wu1,2, Kexin Xie2, Yixuan Zhang2
1Department of Pancreatic and Metabolic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Journal of experimental & clinical cancer research : CR
|March 25, 2025
概括
雷森通过稳定瘤基因驱动KRAS G12C突变肺癌. 用反感性寡核酸向RASON显示了治疗潜力,并与KRAS G12C抑制剂协同用于非小细胞肺癌治疗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症遗传学 癌症遗传学
背景情况:
- 克拉斯是人类癌症的关键瘤基因,克拉斯G12C突变在非小细胞肺癌 (NSCLC) 中普遍存在.
- 现有的KRAS G12C抑制剂面临临临床耐药性的挑战,需要更深入地了解潜在的瘤信号.
- 在此之前,RASON被确定为胰腺癌中KRAS G12D/V信号的调节者.
研究的目的:
- 调查RASON在KRAS G12C驱动NSCLC中的作用.
- 探索向RASON在KRAS G12C突变NSCLC中的治疗潜力.
主要方法:
- 对NSCLC患者队列的免疫组织化学研究,以将RASON表达与进展相关联.
- 在体外和体内测试 (细胞增殖,球体形成,瘤植入,小鼠模型) 来评估RASON的致癌作用.
- 通过RNA-seq,免疫光,免疫沉和生化分析,阐明RASON与KRAS G12C的作用机制和相互作用.
- fagocytosis 试验和流细胞测量,以评估 RASON 对瘤免疫微环境的影响.
- 在异种移植模型中进行药理抑制研究,以确定治疗疗效.
主要成果:
- 在KRAS G12C突变NSCLC中,RASON过度表达,与预后不佳相关.
- 雷森直接结合并稳定KRAS G12C在其活性GTP结合状态,促进下游信号和瘤生长.
- 雷森淘汰会减少瘤负担,抑制增殖,并通过降低CD47表达来增强抗瘤免疫力.
- 针对RASON的反感性寡核酸体显示出瘤抑制作用,并与AMG-510协同改善抗瘤功效.
结论:
- 雷森是KRAS G12C驱动的肺瘤发生和进展中的关键瘤调节剂.
- 雷森代表了对KRAS G12C突变非小细胞肺癌的有前途的治疗标.
相关概念视频
The Ras Gene
6.1K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.1K
Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
MAPK Signaling Cascades
5.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.0K
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K


